Ariad to resume sale of leukemia drug Iclusig

(Reuters) - Ariad Pharmaceuticals Inc said it will resume selling its leukemia drug, Iclusig, in the United States, nearly two months after sales were halted due to safety concerns. The Food and Drug Administration approved a revised label for the drug including a boxed warning, updated safety information and recommendations regarding dosing. Ariad shares jumped 26 percent to $6.96 in heavy volume trading on Friday. (Reporting by Esha Dey in Bangalore)



via Health News Headlines - Yahoo News http://news.yahoo.com/ariad-resume-sale-leukemia-drug-iclusig-153036748--finance.html